Substance Use and Symptoms of Mental Health Disorders: a Prospective Cohort of Patients With Severe Substance Use Disorders in Norway

Christer Frode Aas (christer.frode.aas@helse-bergen.no)
Helse Bergen HF  https://orcid.org/0000-0002-6469-9354

Jørn Henrik Vold
Haukeland University Hospital: Haukeland Universitetssjukehus

Rolf Gjestad
Haukeland University Hospital: Haukeland Universitetssjukehus

Svetlana Skurtveit
The Norwegian Institute of Public Health

Aaron G. Lim
University of Bristol

Kristian Varden Gjerde
Haukeland University Hospital: Haukeland Universitetssjukehus

Else Marie Løberg
Haukeland University Hospital: Haukeland Universitetssjukehus

Kjell Arne Johansson
University of Bergen: Universitetet i Bergen

Lars Thore Fadnes
University of Bergen: Universitetet i Bergen

Research

Keywords: Substance use disorder, substance abuse, mental disorder, psychological distress, mental health problems, opioid substitution treatment, opioid dependence

DOI: https://doi.org/10.21203/rs.3.rs-125971/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

There is high co-occurrence of substance use disorders (SUD) and mental health disorders. We aimed to assess impact of substance use patterns and sociodemographic factors on mental health distress using the ten-item Hopkins Symptom Checklist (SCL-10) over time.

Methods

Nested prospective cohort study of 707 participants with severe SUD across nine opioid-agonist-therapy outpatient clinics and low-threshold municipality clinics in Norway, during 2017-2020. Descriptive statistics were derived at baseline and reported by means and standard deviation (SD). A linear mixed model analysis was used to assess the impact of substance use patterns and sociodemographic factors on SCL-10 sum score with beta coefficients with 95% confidence intervals (CI).

Results

Mean (SD) SCL-10 score was 2.2 (0.8) at baseline with large variations across patients. We observed more symptoms of mental health disorders among people with frequent use of benzodiazepines (beta 3.6, CI: 2.4; 4.8), cannabis (1.3, CI: 0.2; 2.5), opioids (2.7, CI: 1.1; 4.2), and less symptoms among people using frequently stimulants (-2.7, CI: -4.1; -1.4) compared to no or less frequent use. Females (1.8, CI: 0.7; 3.0) and participants with debt worries (2.2, CI: 1.1; 3.3) and unstable living conditions (1.7, CI: 0.0; 3.3) had also higher burden of mental health symptoms. There were large individual variations in SCL-10 score from baseline to follow-up, but no consistent time trends indicating change over time for the whole group. 65 % of the cohort had a mean score >1.85, the standard reference score.

Conclusions

People with SUD are considerably more likely to have symptoms of mental health disorders compared to the general population. The lack of association between substance use patterns on change in mental health symptoms over time could suggest that the differences observed were indicating flattening of effects or self-medication to larger degree than medication-related decline in mental health. This call for better individualized mental health assessment and patient care.

1. Background

Substance use disorders (SUD) contribute to 11.8 million deaths globally per year and 1.5% of the global disease burden [1]. It is estimated that 2% of the world population has a SUD, with some countries reporting a prevalence of SUD greater than 5% [1]. More than half of the people with a SUD will experience a mental health disorder at some point during their lives [2, 3], yet it is less clear whether mental health disorders develop mostly as a consequence of substance use or vice versa [4]. The co-occurrence of SUD and mental health disorders may be attributed to shared genetic vulnerability and pathophysiological
processes possibly related to specific neurotransmitter systems [5, 6]. Even though most research has been in relation to amphetamines, cannabis and alcohol, comorbid mental health symptoms are probably also the case for the more severe forms of SUD like opioid dependence. However, less is known about the prevalence, predictors and change over time of mental health symptoms in these patient groups, limiting optimal clinical care. It has been suggested that these comorbidities often are under-recognized in clinical settings [7, 8].

Among people with SUD in Europe, the most prevalent mental health disorders in epidemiological studies are personality disorders (51%), mood disorders (35%), attention-deficit hyperactivity disorder (30%) and anxiety disorders (27%) [9–12]. Poor quality of life [13], concurrent drug use, including benzodiazepine misuse (e.g. without prescription, higher frequency or dosage prescribed), is common and prevalent among SUD and people enrolled in opioid agonist therapy (OAT) [14, 15]. Some research suggest that benzodiazepine misuse are associated with other substance use, aggressive behavior and worsening mental health symptoms and disorders [16, 17]. Having a SUD, or a mental health disorder, is also likely to increase the risk for misuse of opioids [18, 19]. Opioid dependence is the most severe SUD, and of all illegal drugs, opioids represents the most fatal risk factor, the highest disease burden and most urgent demand for treatment [20, 21]. In addition, substance use patterns of cannabis and stimulants especially frequent use, are found to be associated with residual cognitive impairment and poor mental health [22–24].

Attention to mental health symptoms could perhaps better facilitate and optimize individualized mental health care and SUD treatment to these marginalized and vulnerable populations in low-threshold settings and OAT programs. It is therefore vital to identify and assess mental health among the SUD population, as the co-occurrence of SUD and mental health disorders are likely to be underserved by current mental health systems [25, 26].

The aims of this prospective cohort study was to examine prevalence and change over time of mental health symptoms using the ten-item Hopkins Symptom Checklist (SCL-10) among people with severe substance use disorders (SUD) in Norway. In addition, the study aimed to assess potential predictors of mental health symptoms and change in symptom burden over time from substance use patterns and injecting use while also adjusting for level of education, living conditions, age and gender.

### 2. Methods

#### 2.1 Study design and setting

This study is a nested prospective cohort study linked to the multicenter INTRO-HCV study [27]. The data was collected from May 2017 until July 2020 as part of an annual health assessment among people with SUD in nine OAT outpatient clinics in Bergen and Stavanger and two low-threshold municipality clinics in Bergen. The OAT clinics have implemented an integrated treatment and care model where patients are followed-up on a near daily basis by general and specialized nurses, psychologists and physicians who
are under specialization- or specialized in addiction medicine. Buprenorphine-based and methadone are the two main OAT medications [28]. People with SUD in the municipality clinics are followed-up by social workers, general nurses and physicians specialized in family medicine. The INTRO-HCV study have employed trained research nurses who collected and completed the structured patient interviews, which were recorded in a health register using an electronic data collection software (CheckWare).

2.2 Study sample

The study sample was comprised of two groups of patients; individuals diagnosed with opioid dependence (F11.2) according to International Classification of Diseases version 10 (ICD-10) [29], which were enrolled in OAT during the study period, and people with severe SUD and injecting drug use being followed-up at municipality clinics. All included individuals were 18 years or older at time of inclusion and signed a written informed consent to partake in the study. Altogether 1042 SCL-10 measurements were included from 707 participants. Of the 707 participants with SCL-10 measures at baseline and 268 (38%) were included in a follow-up assessment with 67 (10%) having at least three annual measuring points. The mean time between SCL-10 measurements was 364 days (standard deviation (SD) 133). Table 1 shows details on clinical and sociodemographic characteristics of the study sample.

2.3 Assessment

Measuring mental health status: Hopkins symptom check list (SCL-10)

The SCL-10 is a structured and self-administrated questionnaire, designed to measure symptoms of mental health disorders and psychological distress, and is widely used for both clinical and epidemiological purposes [30–32]. The SCL-10 involves ten items (suddenly scared for no reason, feeling fearful, faintness, dizziness or weakness, feeling tense, blaming yourself, difficulties falling asleep, feeling of worthlessness, feeling blue, feeling hopeless, and feeling everything is an effort), which are each scored on four dimensions from not bothered at all (item score = 1) to extremely bothered (item score = 4). Scores were summed and divided by the number of items answered to derive the mean item score. Mean scores vary between one and four, where the latter assumes extremely bothered. SCL-10 mean item scores were used for descriptive analyses while SCL-10 sum scores were used in linear mixed model (LMM) analyses. Furthermore, the mean item scores were calculated by gender, age, level of education, and living conditions at baseline. By introducing a cut-off point one can interpret the proportion of the respondents with symptoms of mental health disorders. A mean score of 1.85 for SCL-10 has been recommended as a threshold for indicating substantial mental health distress [31].

2.4 Study variables; baseline, OAT, clinical and sociodemographic factors

Baseline was defined as the time when the first SCL-10 measure was completed upon the participant's first annual health assessment. Subsequent SCL-10 measures at the next health assessment(s) were listed chronologically and included as follow-up. Being on OAT was defined as receiving either buprenorphine-based or methadone medication at baseline. Moreover, the OAT ratio, which corresponds
to the received dose of OAT medication per day divided by expected mean dose (buprenorphine 18 mg or methadone 90 mg) according to World Health Organization [33], was calculated per OAT patient. For the clinical factors we defined injecting substances as having injected any substance during the last 12 months, and frequent substance use as using a substance more than once weekly during the last 12 months according to the subcategories of alcohol, cannabis, stimulants (amphetamine/methamphetamine/cocaine), opioids (non-OAT), and benzodiazepines (including z-hypnotics).

2.5 Statistical analysis

All descriptive analyses were performed using STATA/SE 16.0. Expectation-maximization (EM) imputation and LMM analyses were performed in IBM SPSS version 26.0. Statistical significance was set at the p < 0.05 level. Missing values of SCL-10, clinical and sociodemographic variables, which included substance use, injecting substance use, educational level, worrying debt situation, and living conditions were assumed to be missing at random when performing EM imputation. There were missing values for 3.4% of these values, which were subsequently replaced with the estimated values by EM imputation according to Enders (2010) [34]. Time was defined as years from baseline.

A LMM analyses were used to evaluate the impact of clinical and sociodemographic factors on the SCL-10 sum score. Firstly, we ran a LMM analysis where each defined predictor variable was set against time, to assess whether the predictor variable changed over time. There were no clinical significant changes in these variables when analyzed separately as outcome variables – with the time variable being the exposure variable (data not shown). Thus, these predictor variables were included as constant and time-independent variables in further analyses. Secondly, a new LMM analysis was generated where these time-independent predictor variables were set against the SCL-10 sum score being the outcome variable. In addition, we added a time interactional to each predictor variable to investigate if time impacted changes of SCL-10 given each predictor. The predictor variables, on the baseline level and change in SCL-10 sum score, represented as main effects and interaction effects with time. The model was a random intercept fixed slope model with restricted maximum likelihood regression. Based on the full information maximum likelihood estimator all available data in the outcome variable were used.

3. Results

3.1 Basic characteristics of the study sample

Seventy-one percent of the study sample were male, mean (SD) age of 43 (11) at baseline and 45 (10) at follow-up for the whole cohort (Table 1). Approximately 40% had completed upper secondary school. Most participants (88%) had a stable living condition and 41% had a concerning debt situation. Eighty-two percent of the study sample was in OAT, of which 61% and 38% received buprenorphine-based medication and methadone, respectively. Over half had injected substances at least once during the last year, while 71% reported frequent substance use; most prevalent substances being cannabis (50%) and benzodiazepines (38%).
Table 1
Basic characteristics of study sample

| Participants, n (%) | Baseline (n = 707) | Follow-up (n = 268) |
|---------------------|--------------------|--------------------|
| **Gender**          |                    |                    |
| Male                | 500 (71)           | 208 (78)           |
| Female              | 207 (29)           | 60 (22)            |
| **Age, n (%)**      |                    |                    |
| 18–29               | 83 (12)            | 25 (9)             |
| 30–39               | 203 (29)           | 71 (26)            |
| 40–49               | 217 (31)           | 87 (32)            |
| 50–59               | 161 (23)           | 71 (26)            |
| ≥ 60                | 43 (6)             | 14 (5)             |
| Mean (SD)           | 43 (11)            | 45 (10)            |
| **Highest education completed, n (%)** | | |
| Not completed lower secondary school | 41 (6) | 15 (6) |
| Completed lower secondary school (9 years) | 309 (44) | 128 (48) |
| Completed upper secondary school (12 years) | 285 (40) | 99 (37) |
| Completed under or postgraduate studies (≥ 12 years) | 72 (10) | 26 (10) |
| **Current living conditions, n (%)** | | |
| Stable (owned, rented or incarcerated) | 619 (88) | 242 (90) |
| Unstable (homeless, with family/friends) | 88 (12) | 26 (10) |
| **Worrying debt situation** | | |
| 292 (41) | 116 (43) |
| **Participants enrolled in OAT, n (%)** | | |
| 590 (83) | 248 (93) |
| **OAT medications of those; n (%)** | | |
| Methadone | 224 (38) | 110 (44) |
| Buprenorphine-based | 357 (61) | 134 (54) |
| **OAT treatment ratio*, mean (SD)** | 0.9 (0.4) | 0.9 (0.3) |
| **Injecting and frequent substance use past 12 months, n (%)** | | |
| Injected at least once | 352 (54) | 142 (53) |
| Participants, n (%)                                      | Baseline (n = 707) | Follow-up (n = 268) |
|--------------------------------------------------------|--------------------|--------------------|
| Alcohol                                                | 165 (25)           | 67 (25)            |
| Cannabis                                               | 329 (50)           | 145 (55)           |
| Stimulants (amphetamine/methamphetamine/cocaine)      | 183 (28)           | 73 (27)            |
| Opioids (other than OAT)                               | 103 (16)           | 29 (11)            |
| Benzodiazepines                                        | 248 (38)           | 104 (39)           |

SD = standard deviation, OAT = Opioid agonist therapy,

*OAT ratio = ratio between daily OAT medication dose divided by expected mean daily dose; for buprenorphine 18mg, buprenorphine-naloxone 18/4.5mg or methadone 90mg.

Frequent substance use was defined as using substance at least weekly during the past 12 months

### 3.2 SCL-10 scores at baseline and follow-up

The mean (SD) of the SCL-10 item scores was 2.2 (0.8) (Table 2) at baseline. The distribution was sharply-peaked (kurtosis: 2.2) and slightly right-skewed (skewness: 0.4). The lowest mean (SD) item score (SD) was found for *suddenly scared for no reason* at 1.9 (1.1) and the highest score 2.5 (1.2) for *difficulty in falling asleep* (Fig. 1 and Additional File 1). Overall, females reported mean (SD) SCL-10 item score of 2.3 (0.8) and men 2.2 (0.8). People with unstable living conditions reported more symptoms of mental disorders than people with stable living conditions. Among OAT treatment, people on methadone reported mean (SD) SCL-10 of 2.3 (0.7) and buprenorphine-based medications at 2.2 (0.8).
Table 2
Baseline SCL-10 mean item scores and standard deviation (SD) by gender, age and sociodemographic factors

|                                | SCL-10 |
|--------------------------------|--------|
|                                | Mean   | SD    |
| **Total**                      | 2.22   | 0.76  |
| **Gender, n 707**              |        |       |
| Male                           | 2.17   | 0.76  |
| Female                         | 2.32   | 0.75  |
| **Age, n 707**                 |        |       |
| 18–29                          | 2.31   | 0.78  |
| 30–39                          | 2.20   | 0.75  |
| 40–49                          | 2.25   | 0.79  |
| 50–59                          | 2.16   | 0.72  |
| ≥ 60                           | 2.14   | 0.73  |
| **Highest level of education, n 705** |   |       |
| Not completed lower secondary school | 2.46 | 0.78 |
| Completed lower secondary school (9 years) | 2.24 | 0.78 |
| Completed upper secondary school (12 years) | 2.14 | 0.72 |
| Completed undergraduate studies (≤ 15 years) | 2.28 | 0.77 |
| Completed postgraduate studies (≥ 15 years) | 2.16 | 0.66 |
| **Current living conditions, n 705** |   |       |
| Stable (owned, rented or incarcerated) | 2.19 | 0.74 |
| Unstable (homeless, with family/friends) | 2.40 | 0.84 |
| **Enrolled in OAT and by medication, n 583** |   |       |
| Methadone                      | 2.28   | 0.71  |
| Buprenorphine                  | 2.15   | 0.77  |

SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/psychological distress, SD = standard deviation, OAT = opioid agonist therapy

We found vast individual dissimilarities in subjective mental health symptoms at baseline (Additional File 2); minimum and maximum mean SCL-10 item score was one and four, respectively. Thirty-three
participants (4.7%) reported a mean of one; meaning not bothered at all on any items, while three participants (0.4%) were extremely bothered on all items. Sixty-five percent of the cohort reported a mean SCL-10 above the 1.85 cut-off point, which is recommended as a predictor of mental disorder [31] as shown in the Pen's Parade below.

Altogether 268 (38%) of the 707 participants at baseline had SCL-10 measures at two data points. As shown in above, individual SCL-10 score at first follow-up are indicated with grey points and individual changes from baseline with vertical lines. Sharp changes go in both positive and negative directions and appear considerable for some.

### 3.3 Impact of substance use patterns, clinical and sociodemographic factors on baseline level and change in SCL-10 sum score

Using a LMM analysis, we found higher SCL-10 sum scores at baseline for females (SCL-10 sum score: 1.8, 95% confidence interval (CI): 0.7 to 3.0) compared to men, people with unstable living conditions (1.7, CI: 0.0 to 3.3) and having a worrying debt (2.2, CI: 1.1 to 3.3) compared to people with stable living conditions and non-worrying debt, respectively. For substances, frequent use of cannabis (1.3, CI: 0.2 to 2.5), other opioids (2.7, CI: 1.1 to 4.2) and benzodiazepines (3.6, CI: 2.4 to 4.8) were associated with higher SCL-10 scores at baseline compared to people with no or non-frequent use of these substances (Table 3). On the other hand, frequent use of stimulants was associated with lower SCL-10 sum score at baseline (-2.7, CI: -4.1 to -1.4) compared with people with no or less frequent use. There were no significant time interactions between any of the substance use patterns and changes in the SCL-10 sum score, nor were there any significant time interactions with sociodemographic characteristics.
|                         | Effect estimate (baseline) | Time trend (change per year) |
|-------------------------|----------------------------|------------------------------|
| **Fixed effects**       |                            |                              |
| n = 707                 |                            |                              |
| Factor impact* on SCL-10 sum score at baseline and changes per year from baseline |                            |                              |
| SCL-10 sum score        | 18.1 (15.9 to 20.2)        | 0.6 (-1.6 to 2.9)            |
| Female                  | 1.8 (0.7 to 3.0)           | 0.4 (-0.9 to 1.8)            |
| Age per 10 years        | 0.0 (-0.1 to 0.0)          | 0.0 (0.0 to 0.1)             |
| **Clinical factors**    |                            |                              |
| Injecting substance use |                            |                              |
| Injecting at least once last 12 months | 0.6 (-0.7 to 1.8) | -0.3 (-1.6 to 1.0) |
| **Frequent use of substances** |                    |                              |
| Alcohol                 | 0.7 (-0.6 to 1.9)          | 0.1 (-1.2 to 1.4)            |
| Cannabis                | 1.3 (0.2 to 2.5)           | 0.3 (-0.9 to 1.4)            |
| Stimulants (amphetamines/ cocaine) | -2.7 (-4.1 to -1.4) | -0.2 (-1.6 to 1.3) |
| Opioids (other than opioid dispensed on OAT) | 2.7 (1.1 to 4.2) | -2.6 (-4.7 to -0.4) |
| Benzodiazepines         | 3.6 (2.4 to 4.8)           | -0.4 (-1.7 to 0.8)           |
| **Sociodemographic factors** |                         |                              |
| Level of education      | -0.1 (-0.7 to 0.6)         | -0.6 (-1.3 to 0.1)           |
| Unstable living conditions | 1.7 (0.0 to 3.3)         | 1.1 (-1.0 to 3.3)            |
| Worries debt situation  | 2.2 (1.1 to 3.3)           | 0.4 (-0.7 to 1.6)            |

SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/psychological distress, CI = confidence interval

*Age per 10 years (centered according to mean age 43 years), level of education was coded 0-4 with 4 as the highest educational level, living conditions; unstable situation homeless or non-permanent residence, worrying debt situation: including any legal or illegal fees and debt, injecting substance use: during last 12 months.
4. Discussion

In this study, we found that 65% of people with SUD have symptoms of mental health disorders and psychological distress. Mental health symptoms were particularly prevalent among females, people with frequent use of cannabis, non-OAT opioids, and benzodiazepines compared to men and people with no or less frequent use of these substances. Interestingly, there were no clear associations between substance use patterns and change in mental health symptoms over time. This could suggest that the differences observed were indicating self-medication to a larger degree than medication-related decline in mental health.

People with SUD are a heterogeneous population; fifteen and thirty-five percent reported lower mean SCL-10 item scores compared to the general population and the standard reference score for symptoms of mental health disorders, respectively. Despite vast intra-individual variations in SCL-10 score from baseline to first follow-up, going in both directions, there were no time trends indicating change over time for the total study sample. This indicates that mental health disorders and psychological distress persist over time for this group and we are not able to explain the huge shift, positive and negative, in mental status of many individuals.

We found that mental health symptoms at baseline were associated with a worrying debt situation, unstable living conditions and a frequent use of some of the substances. Severe debt has been found to correlate with poor mental health in a systematic review summarizing a number of studies [35]. There are also several studies suggesting a strong relationships between substance use and psychological distress, despite hardship to establish exact causality [36–38]. In our study, use of cannabis, non-OAT opioids and benzodiazepines were co-occurring with mental health distress at baseline, while the opposite was seen for stimulants. There were no changes in time trends between use of substances and mental health symptoms. One hypothesis for these findings could be that the associations at baseline might be due to reverse causality, i.e. that participants with substantial mental health symptoms use substances to self-medicate symptoms [39]. It is also possible that there is a “flattening effect” and that potential negative impact of substances are more substantial at an earlier phase and that the change in later phases are less pronounced.

Other research indicate that high doses of benzodiazepines reduce social functioning, and that it may also increase psychological distress and worsen mental health [16, 40], and misuse of benzodiazepines is seen among both SUD and psychiatric populations alike [41]. Similarly, the use of stimulants, in particular methamphetamine, has been associated with poor mental health outcomes [23]. Self-medication of attention deficit hyperactivity disorder (ADHD) with stimulants could be one explanation for these findings. Yet one study found that high ADHD symptom burden was associated with higher mental distress and use of simulants among OAT patients [42]. It is estimated that up to a third of patients in OAT have ADHD and previously we have found that coverage of central acting stimulants in this patient group is very low [12, 43, 44]. An alternative explanation could be that stimulants have a
direct positive impact on mental health symptoms among these patients. However, the time trend analyses does not support these hypotheses.

Although prevalence of mental disorders and SUD comorbidity has been found to vary among European countries; research consistently shows a high total prevalence of around 50%, with depression, anxiety disorders and personality disorders being the most frequent [9]. However, some facility based studies indicate an even higher comorbidity prevalence as people with severe symptoms are more likely to seek support; 70% for personality disorders [3] and a lifetime substance-independent mental disorder was found in nine out of ten patients enrolled in treatment facilities [45]. Comorbid mental health disorders and SUD have been found to be associated with poor treatment outcomes and show a higher psychopathological severity compared to people with a single disorder [46–48], and this underlies the importance of assessing mental health status in clinical settings among people with SUD. We endorse that evaluation of mental health and linkage to mental health care services should be included in OAT programs and low-threshold SUD clinics; be gender-sensitive and follow an integrated treatment approach, which have been found superior compared to separate treatment plans [49–51].

The major strength of this study is the relatively large sample size of a “hard-to-reach” population of people with SUD as well as a cohort design. However, there are some limitations. Firstly, only a minority contributed to the prospective analyses (268/707). To reduce the potential for selection bias between the sub-group with follow-up SCL-10 measurements presented in Fig. 2 and the baseline cohort, we conducted an inverse probability weighted analysis. Our study sample is also mainly relevant for people with opioid dependence being enrolled in OAT treatment as most were in this group. Thus, our research might not be generalized to other groups with SUD. Moreover, both in the OAT and low-threshold SUD clinics, patient- and system delays contributed to non-accurate annual health assessments, which could in turn affect both answers and results. Thirdly, the SCL-10 has limitations. It is not a diagnostic tool for mental health disorders and is no replacement for clinical interviews and more comprehensive psychiatric instruments among people with SUD. Literature also suggests that the SCL-10 predicts depression and anxiety better than other diagnosis, and that some 50–60% of the patients identified with symptoms of mental disorders qualify for at least one or more mental disorders when assessed clinically [31, 52, 53].

5. Conclusion

People with SUD have considerably more symptoms of mental health disorders and psychological distress compared to the general population. However, this is a diverse and dynamic population with extreme individual variations. Around one-third have few symptoms of mental health disorders. This emphasizes the importance of consideration and evaluation of symptoms of mental health disorders and psychological distress in both OAT and low-threshold SUD clinics to further improve personalized patient care. Mental health problems were particularly observed among females, people with frequent use of cannabis, opioids, and benzodiazepines, and less among people using amphetamines. Time trend analyses could suggest that the differences observed indicates self-medication or a flattening effect
rather than medication-related decline in mental health. Studies with long term follow-up or experimental design is needed to confirm these potential effects better.

6. List Of Abbreviations

ADHD Attention deficit hyperactivity disorder
EM Expectation-maximization imputation
INTRO-HCV Integrated treatment of hepatitis C virus infection
HCV Hepatitis C virus infection
LMM Linear mixed model
OAT Opioid agonist therapy
SCL-10 Hopkins Symptom Check List 10
SCL-25 Hopkins Symptom Check List 25
SUD Substance use disorder

Declarations

Ethical approval and consent to participate

The study was approved by the Regional committee for medical and health research ethics (no. 2017/51/REK vest). It was conducted in accordance with the Helsinki Declaration and STROBE guidelines. All included participants signed a written consent to partake in the study.

Consent for publication

Not applicable. No personal details on any of the participants are reported in the manuscript, tables or figures.

Availability of data and material

Dataset used for SCL-10 for this publication may be available in an anonymous and shortened version upon contacting the corresponding author.

Competing interests

None of the authors have competing interests.

Funding
This study is part of the main INTRO-HCV study, which was funded by The Norwegian Research Council (no. 269855) and the Western Norway Regional Health Authority ("Åpen prosjektstøtte) with Department of Addiction Medicine, Haukeland University Hospital as responsible institution. The funders had no role in the study design, data collection and analyzes, decision to publish, nor preparation of any content in the manuscript. Two of the authors, CFA and JHV, are funded from the above research grant, whereas the other authors are funded by their respective affiliations.

Authors’ contributions

This observational study was led by CFA in terms of study design, analyzes, drafting and writing the article. JHV, RG and AGL were particularly involved with acquisition of data, analyses and interpretation. Figures were made by AGL. KAJ, LTF, SS, JHV, AGL, KVG, RG and EML contributed to the conception, writing, and revising the draft(s) critically. All authors have read and approved the version to be published.

Acknowledgements

Christer Kleppe, data protecting officer, Helse Bergen for his valuable contribution and guidance in data management. We also thank Nina Elisabeth Eltvik for valuable help and input during the planning and preparation phases.

References

1. Global Burden of Disease Collaborative Network: The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The lancet Psychiatry 2018, 5(12):987-1012.

2. Santucci K: Psychiatric disease and drug abuse. Current opinion in pediatrics 2012, 24(2):233-237.

3. Burdzovic Andreas J, Lauritzen G, Nordfjaern T: Co-occurrence between mental distress and poly-drug use: a ten year prospective study of patients from substance abuse treatment. Addictive behaviors 2015, 48:71-78.

4. Chassin L, Sher KJ, Hussong A, Curran P: The developmental psychopathology of alcohol use and alcohol disorders: research achievements and future directions. Dev Psychopathol 2013, 25(4 Pt 2):1567-1584.

5. Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, Medhus S, Tanum L, Franck J: Amphetamine-induced psychosis—a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012, 12:221.

6. Løberg EM, Helle S, Nygård M, Berle JO, Kroken RA, Johnsen E: The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Front Psychiatry 2014, 5:159.

7. European Monitoring Centre for Drugs and Drug Addiction: Komorbiditet — samførekomst av narkotikamissbruk och psykisk stöming. Ett underskattat tillstånd. In.; 2004.
8. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet (London, England)* 2015, **385**(9963):117-171.

9. European Monitoring Centre for Drugs and Drug Addiction: *Co-morbid substance use and mental disorders in Europe: a review of the data*. In.; 2013.

10. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of general psychiatry* 2004, **61**(8):807-816.

11. Hall W: What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders? *Drug and alcohol review* 1996, **15**(2):157-170.

12. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA: Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. *Drug and alcohol dependence* 2012, **122**(1-2):11-19.

13. Aas CF, Vold JH, Skurtveit S, Lim AG, Ruths S, Islam K, Askildsen JE, Løberg EM, Fadnes LT, Johansson KA: Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. *Substance abuse treatment, prevention, and policy* 2020, **15**(1):68.

14. Franklyn AM, Eibl JK, Gauthier G, Pellegrini D, Lightfoot NE, Marsh DC: The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. *Harm reduction journal* 2017, **14**(1):6.

15. Vold JH, Aas C, Skurtveit S, Odsbu I, Chalabianloo F, Reutfors J, Halmøy A, Johansson KA, Fadnes LT: Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. *BMJ open* 2020, **10**(8):e036860.

16. Votaw VR, Geyer R, Rieselbach MM, McHugh RK: The epidemiology of benzodiazepine misuse: A systematic review. *Drug and alcohol dependence* 2019, **200**:95-114.

17. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI: Benzodiazepine use and aggressive behaviour: a systematic review. *The Australian and New Zealand journal of psychiatry* 2014, **48**(12):1096-1114.

18. Davis MA, Lin LA, Liu H, Sites BD: Prescription Opioid Use among Adults with Mental Health Disorders in the United States. *Journal of the American Board of Family Medicine : JABFM* 2017, **30**(4):407-417.

19. Cragg A, Hau JP, Woo SA, Kitchen SA, Liu C, Doyle-Waters MM, Hohl CM: Risk Factors for Misuse of Prescribed Opioids: A Systematic Review and Meta-Analysis. *Annals of emergency medicine* 2019, **74**(5):634-646.

20. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN: The Burden of Opioid-Related Mortality in the United States. *JAMA network open* 2018, **1**(2):e180217.
21. European Monitoring Centre for Drugs and Drug Addiction: European Drug Report. Trends and Developments. In.; 2019.

22. Hall W, Degenhardt L: The adverse health effects of chronic cannabis use. Drug testing and analysis 2014, 6(1-2):39-45.

23. McKetin R, Leung J, Stockings E, Huo Y, Foulds J, Lappin JM, Cumming C, Arunogiri S, Young JT, Sara G et al: Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. EClinicalMedicine 2019, 16:81-97.

24. Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, Ali R, Tran LT, Rehm J, Torrens M et al: Responding to global stimulant use: challenges and opportunities. Lancet (London, England) 2019, 394(10209):1652-1667.

25. Đào GJ, Brunelle C, Speed D: Impact of Substance Use and Mental Health Comorbidity on Health Care Access in Canada. J Dual Diagn 2019, 15(4):260-269.

26. Sheidow AJ, McCart M, Zajac K, Davis M: Prevalence and impact of substance use among emerging adults with serious mental health conditions. Psychiatr Rehabil J 2012, 35(3):235-243.

27. Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgard O, Vickerman P et al: Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC infectious diseases 2019, 19(1):943.

28. Waal H BK, Clausen T, Lillevold PH, and Skeie I.: SERAF Report: Status 2017. MAR 20 years. Status, evaluations and perspectives. In.: The Norwegian Centre for Addiction Research (SERAF); 2018.

29. Classifications: ICD-10 online versions [https://www.who.int/classifications/icd/icdonlineversions/en/]

30. Schmalbach B, Zenger M, Tibubos AN, Kliem S, Petrowski K, Brähler E: Psychometric Properties of Two Brief Versions of the Hopkins Symptom Checklist: HSCL-5 and HSCL-10. Assessment 2019:1073191119860910.

31. Strand BH, Dalgard OS, Tambs K, Rognerud M: Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nordic journal of psychiatry 2003, 57(2):113-118.

32. Kleppang AL, Hagquist C: The psychometric properties of the Hopkins Symptom Checklist-10: a Rasch analysis based on adolescent data from Norway. Family practice 2016, 33(6):740-745.

33. World Health Organization: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. In.; 2009.

34. Enders CK: Applied Missing Data Analysis. New York: The Guilford Press; 2010.

35. Richardson T, Elliott P, Roberts R: The relationship between personal unsecured debt and mental and physical health: a systematic review and meta-analysis. Clinical psychology review 2013, 33(8):1148-1162.
36. Kelly AB, Chan GC, Mason WA, Williams JW: The relationship between psychological distress and adolescent polydrug use. *Psychol Addict Behav* 2015, **29**(3):787-793.

37. Sopheab H, Suy S, Chhea C, Chhit S, Mun P, Bui TC: Psychological distress among Cambodian people who use drugs. *Drug and alcohol review* 2020, **39**(1):66-70.

38. Booth BM, Curran G, Han X, Wright P, Frith S, Leukefeld C, Falck R, Carlson RG: Longitudinal relationship between psychological distress and multiple substance use: results from a three-year multisite natural-history study of rural stimulant users. *J Stud Alcohol Drugs* 2010, **71**(2):258-267.

39. Turner S, Mota N, Bolton J, Sareen J: Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature. *Depress Anxiety* 2018, **35**(9):851-860.

40. Lugoboni F, Mirijello A, Faccini M, Casari R, Cossari A, Musi G, Bissoli G, Quaglio G, Addolorato G: Quality of life in a cohort of high-dose benzodiazepine dependent patients. *Drug and alcohol dependence* 2014, **142**:105-109.

41. McHugh RK, Peckham AD, Björgvinsson T, Korte FM, Beard C: Benzodiazepine misuse among adults receiving psychiatric treatment. *Journal of psychiatric research* 2020, **128**:33-37.

42. Fiksdal Abel K, Ravndal E, Clausen T, Bramness JG: Attention Deficit Hyperactivity Disorder Symptoms are Common in Patients in Opioid Maintenance Treatment. *European addiction research* 2017, **23**(6):298-305.

43. Subramaniam GA, Stitzer MA: Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. *Drug and alcohol dependence* 2009, **101**(1-2):13-19.

44. Vold JH, Aas C, Skurtveit S, Odsbu I, Chalabianloo F, Halmøy A, Johansson KA, Fadnes LT: Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017. *BMC psychiatry* 2020, **20**(1):119.

45. Bakken K, Landheim AS, Vaglum P: Primary and secondary substance misusers: do they differ in substance-induced and substance-independent mental disorders? *Alcohol and alcoholism (Oxford, Oxfordshire)* 2003, **38**(1):54-59.

46. Stahler GJ, Mennis J, Cotlar R, Baron DA: The influence of neighborhood environment on treatment continuity and rehospitalization in dually diagnosed patients discharged from acute inpatient care. *The American journal of psychiatry* 2009, **166**(11):1258-1268.

47. Langås AM, Malt UF, Opjordsmoen S: Comorbid mental disorders in substance users from a single catchment area—a clinical study. *BMC psychiatry* 2011, **11**:25.

48. Szerman N, Lopez-Castroman J, Arias F, Morant C, Babin F, Mesías B, Basurte I, Vega P, Baca-García E: Dual diagnosis and suicide risk in a Spanish outpatient sample. *Substance use & misuse* 2012, **47**(4):383-389.

49. Kelly TM, Daley DC: Integrated treatment of substance use and psychiatric disorders. *Social work in public health* 2013, **28**(3-4):388-406.
50. Donald M, Dower J, Kavanagh D: Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials. *Soc Sci Med* 2005, **60**(6):1371-1383.

51. Rezansoff SN, Moniruzzaman A, Somers JM: Temporal associations between medication adherence for patients with schizophrenia and opioid dependence: A 17-year Canadian Cohort Study. *Schizophr Res* 2019, **210**:157-163.

52. Syed HR, Zachrisson HD, Dalgard OS, Dalen I, Ahlberg N: Concordance between Hopkins Symptom Checklist (HSCL-10) and Pakistan Anxiety and Depression Questionnaire (PADQ), in a rural self-motivated population in Pakistan. *BMC psychiatry* 2008, **8**:59.

53. Sandanger I, Moum T, Ingebrigtsen G, Dalgard OS, Sørensen T, Bruusgaard D: Concordance between symptom screening and diagnostic procedure: the Hopkins Symptom Checklist-25 and the Composite International Diagnostic Interview I. *Social psychiatry and psychiatric epidemiology* 1998, **33**(7):345-354.

**Figures**

![SCL-10 Baseline](image)

**Figure 1**
Proportion of SCL-10 item scores at baseline. SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/psychological distress. The figure displays the proportion of patients responses on the ten item scale, from not bothered at all (item score = 1) to extremely bothered (item score = 4).

**Figure 2**

Pen's Parade: Distribution of mean SCL-10 item scores at baseline and follow-up. Pen's Parade: SCL-10 = Symptoms checklist 10; ten items scale for measuring mental health status/psychological distress. The figure displays distribution in SCL-10 mean values at baseline (n=707) and follow up (n=268), represented by fixed black line and vertical grey lines. The dotted lines represent the mean reported SCL-10 score of the Norwegian reference population (1.36) and standard reference of 1.85 indicating one or more mental disorders above this cut-off, respectively. Source: Strand BH, Dalgard OS, Tambs K, Rognerud M: Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nordic journal of psychiatry 2003

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1SCL10.xlsx
- Additionalfile2SCL10.pdf